HIV Protease Inhibitors

Vaccines and Antiviral Agents
In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors
Yasuhiro Koh, Masayuki Amano, Tomomi Towata, Matthew Danish, Sofiya Leshchenko-Yashchuk, Debananda Das, Maki Nakayama, Yasushi Tojo, Arun K. Ghosh, Hiroaki Mitsuya
Vaccines and Antiviral Agents
The Effect of Clade-Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways
Rajintha M. Bandaranayake, Madhavi Kolli, Nancy M. King, Ellen A. Nalivaika, Annie Heroux, Junko Kakizawa, Wataru Sugiura, Celia A. Schiffer
Vaccines and Antiviral Agents
Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance
Madhavi N. L. Nalam, Akbar Ali, Michael D. Altman, G. S. Kiran Kumar Reddy, Sripriya Chellappan, Visvaldas Kairys, Ayşegül Özen, Hong Cao, Michael K. Gilson, Bruce Tidor, Tariq M. Rana, Celia A. Schiffer
Genetic Diversity and Evolution
Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance
Madhavi Kolli, Eric Stawiski, Colombe Chappey, Celia A. Schiffer
Vaccines and Antiviral Agents
Gag Determinants of Fitness and Drug Susceptibility in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1
Chris M. Parry, Arinder Kohli, Christine J. Boinett, Greg J. Towers, Adele L. McCormick, Deenan Pillay
Vaccines and Antiviral Agents
Positive Selection Pressure Introduces Secondary Mutations at Gag Cleavage Sites in Human Immunodeficiency Virus Type 1 Harboring Major Protease Resistance Mutations
Søren Banke, Marie R. Lillemark, Jan Gerstoft, Niels Obel, Louise B. Jørgensen
Vaccines and Antiviral Agents
Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir
Klára Grantz Šašková, Milan Kožíšek, Pavlína Řezáčová, Jiří Brynda, Tatyana Yashina, Ron M. Kagan, Jan Konvalinka
Vaccines and Antiviral Agents
Impact of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457)
Catherine S. Adamson, Kayoko Waki, Sherimay D. Ablan, Karl Salzwedel, Eric O. Freed
Vaccines and Antiviral Agents
Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors
Manabu Aoki, David J. Venzon, Yasuhiro Koh, Hiromi Aoki-Ogata, Toshikazu Miyakawa, Kazuhisa Yoshimura, Kenji Maeda, Hiroaki Mitsuya
Vaccines and Antiviral Agents
Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study
Salerwe Mosebi, Lynn Morris, Heini W. Dirr, Yasien Sayed

Pages